The product consists of an injectable suspension of many millions of living human fibroblast cells, the very cells that are responsible for the repair and maintenance of a youthful state of our skin.
As we age, so do the fibroblast cells in our skin. They become much less active, in fact almost dormant, and many of them die.
This results in the skin becoming less and less able to maintain its youthful state and aging changes progressively occur.
However, the Vavelta® cells are derived from tiny fragment of skin that was originally sampled from a newborn baby so that after development into the cell bank of billions of cells, each identical cell is in its most youthful state possible - these cells are zero years old.
This means that with Vavelta® we will have 'on tap' a limitless supply of these extremely youthful cells with which we can re-populate our skin and entire face and re-order whenever we require.
Previous experience with fibroblast cells sampled from the patient's own skin has led us to expect that this treatment will be useful for long-lasting skin rejuvenation with any area being suitable for treatment.
We also expect that acne scars will be naturally and often permanently repaired by this treatment, without any of the risks or trauma of other currently available options such as laser resurfacing.
Restrictive burns scars too, are expected to be remarkably improved by the new cells, based on Dr Palmer's previous pioneering work in this area.
We expect the benefit of Vavelta® over previously available fibroblast cells sampled from the patient's own skin (Isolagen®) to be due to the fact that the Vavelta® cells are in their most youthful state possible and we therefore expect them to be highly active after treatment.
Furthermore, because they are grown in a cell bank and not custom grown for each patient, they are literally available 'on-tap' whenever required and there are no limitations on the doses that can be obtained and used.
A common concern when first hearing about this treatment is: will the immune system reject and destroy the new cells if they are not sampled from the patient's own skin?
In fact, new research has shown us that fibroblast cells are actually 'immune silent' as they have no foreign proteins (antigens) on their surface and so there are no compatibility issues that arise.
Safety studies have already been completed with Vavelta® and there were no significant adverse events in any of the subjects studied.
If you are interested in finding out more about this new treatment or wish to be given more specific information please contact us so that we can answer your individual questions and if necessary arrange a consultion to advise whether or not it would be suitable for you.
As we age, so do the fibroblast cells in our skin. They become much less active, in fact almost dormant, and many of them die.
This results in the skin becoming less and less able to maintain its youthful state and aging changes progressively occur.
However, the Vavelta® cells are derived from tiny fragment of skin that was originally sampled from a newborn baby so that after development into the cell bank of billions of cells, each identical cell is in its most youthful state possible - these cells are zero years old.
This means that with Vavelta® we will have 'on tap' a limitless supply of these extremely youthful cells with which we can re-populate our skin and entire face and re-order whenever we require.
Previous experience with fibroblast cells sampled from the patient's own skin has led us to expect that this treatment will be useful for long-lasting skin rejuvenation with any area being suitable for treatment.
We also expect that acne scars will be naturally and often permanently repaired by this treatment, without any of the risks or trauma of other currently available options such as laser resurfacing.
Restrictive burns scars too, are expected to be remarkably improved by the new cells, based on Dr Palmer's previous pioneering work in this area.
We expect the benefit of Vavelta® over previously available fibroblast cells sampled from the patient's own skin (Isolagen®) to be due to the fact that the Vavelta® cells are in their most youthful state possible and we therefore expect them to be highly active after treatment.
Furthermore, because they are grown in a cell bank and not custom grown for each patient, they are literally available 'on-tap' whenever required and there are no limitations on the doses that can be obtained and used.
A common concern when first hearing about this treatment is: will the immune system reject and destroy the new cells if they are not sampled from the patient's own skin?
In fact, new research has shown us that fibroblast cells are actually 'immune silent' as they have no foreign proteins (antigens) on their surface and so there are no compatibility issues that arise.
Safety studies have already been completed with Vavelta® and there were no significant adverse events in any of the subjects studied.
If you are interested in finding out more about this new treatment or wish to be given more specific information please contact us so that we can answer your individual questions and if necessary arrange a consultion to advise whether or not it would be suitable for you.
| Tel: 0844 800 1209 |
| 100, Harley Street, London |
| Cross Street, Rothwell, Leeds |
| Preventative and Cosmetic Medicine |
Cell Therapy - Vavelta®
Re-populate your skin with youthful cells
Cell therapy is undoubtedly the future for skin rejuvenation as well as for the repair and restoration to youthful health of many tissues in the body.
Re-populate your skin with youthful cells
Cell therapy is undoubtedly the future for skin rejuvenation as well as for the repair and restoration to youthful health of many tissues in the body.
Within our lifetimes, we will probably see a complete revolution in the field of regenerative medicine, with us becoming able to achieve rejuvenation of areas of the body and cure presently untreatable degenerative diseases in ways that seem like science-fiction at the present time.
Already, the technology exists to grow certain human cells outside the body and multiply them up into cell banks of billions of identical copies of themselves.
To ensure safety, very strict regulations govern the operation of such laboratories which grow and store human cells and rigorous inspections are regularly carried out by the Human Tissue Authority.
Intercytex® is a rapidly developing British company, licensed by the Human Tissue Authority, pioneering the development of new cell therapies in several exciting areas.
Already, the technology exists to grow certain human cells outside the body and multiply them up into cell banks of billions of identical copies of themselves.
To ensure safety, very strict regulations govern the operation of such laboratories which grow and store human cells and rigorous inspections are regularly carried out by the Human Tissue Authority.
Intercytex® is a rapidly developing British company, licensed by the Human Tissue Authority, pioneering the development of new cell therapies in several exciting areas.
Their product Vavelta® has just become available to the public in this country.
We are proud to have been selected, because of Dr Palmer's previous experience in this field, to be one of the first of only a small number of initial centres in the UK where its use is being developed within a specialist physicians' group.
We are proud to have been selected, because of Dr Palmer's previous experience in this field, to be one of the first of only a small number of initial centres in the UK where its use is being developed within a specialist physicians' group.